Sudarshan Pharma to Take 9.5% Stake in US CAR-T Developer MedTherapy Biotechnology, Eyes US Entry

API maker Sudarshan Pharma Industries’ board has approved buying a 9.5% stake in Boston-based MedTherapy Biotechnology, a CAR-T cell and gene therapy company with a GMP plant in New Delhi, as a route into the US market. The deal is expected to close by 31 March 2027.